Trials exploring the effects of GA and IFN-β in patients with an FCDE suggestive of MS have shown that early treatment delays evidence of new disease activity and that it is advantageous to treat immediately after the first clinical signs of MS manifest [7-10]. The gene discussed is IFNB1; the disease is myeloid sarcoma.